Z-2285-2012 Class III Terminated

Recalled by Phadia US Inc — Portage, MI

FDA device recall Z-2285-2012 was initiated by Phadia US Inc on Aug 2, 2012 and is designated Class III. Reason for recall: Customers were not following the labeled assay procedure. This was due to a letter issued to them in 2004 from Phadia GmbH, which indicated that customers could omit the pre-wash step. The omission of… The recall status is terminated (terminated Dec 12, 2012). Affected quantity: 837 kits (96 assays per kit), total of 80,352 individual assays.

Recall details

Product Type
Devices
Report Date
Sep 5, 2012
Initiation Date
Aug 2, 2012
Termination Date
Dec 12, 2012
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
837 kits (96 assays per kit), total of 80,352 individual assays

Product description

PHADIA Varelisa Cardiolipin IgM Cardiolipin autoantibody immunological test system (IgM class antibodies)

Reason for recall

Customers were not following the labeled assay procedure. This was due to a letter issued to them in 2004 from Phadia GmbH, which indicated that customers could omit the pre-wash step. The omission of the pre-wash step, when combined with a change in material source in kit lot #0067, caused elevated results.

Distribution pattern

USA Nationwide.

Code information

Article Number 15696 Lot number #0067

Source

Dataset
openFDA device recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for Z-2285-2012
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for Z-2285-2012. Report a data issue: hello@regdatalab.com.